To assess tumor stemness, CD44 and CD133 staining showed stronger signals in the CAF-Sfrp1 treatment group, indicating higher stemness in tumor cells during tumor formation and progression (Figure 6K). The gene discussed is SFRP1; the disease is neoplasm.